K. Pavelka*, H. Jarosova, O. Sleglova, R. Svobodova, M. Votavova, L. Milani, Z. Prochazka, L. Kotlarova, P. Kostiuk, J. Sliva and A.M. Meroni Pages 1019 - 1026 ( 8 )
Chronic low back pain (CLBP) syndrome represents one of the leading causes of long-term disability worldwide. The prevalence of CLBP has been rising significantly in relation to increasing average life expectancy. CLBP results from chronification of acute low back pain. There are many factors contributing to the CLBP crisis; common etiopathogenetic factors include e.g., functional blockage of intervertebral joints. The treatment of CLBP is complex. An important part of treatment consists of pain pharmacotherapy, for which several groups of drugs are used. The problem lies in the side effects of many of these traditionally used medications. Therefore, new and safer treatment methods are being sought. Innovative options for CLBP pharmacology include injections containing collagen, which can be combined with other traditionally used drugs, which helps reduce dosages and increase the overall safety of CLBP therapy.
Chronic low back pain, chronic pain management, pharmacotherapy of chronic pain, safe therapy of pain, pain control, collagen-containing injections.
Institute of Rheumatology, Prague, Institute of Rheumatology, Prague, Institute of Rheumatology, Prague, Institute of Rheumatology, Prague, Institute of Rheumatology, Prague, University Sapienza, Rome and University of Siena, Edukafarm, Prague, Edukafarm, Prague, Edukafarm, Prague, Third Faculty of Medicine, Charles University, Prague, Department of Orthopedics and Traumatology, Niguarda Hospital, Milano